HIV trial stopped early after good results

BMJ 1997; 314 doi: (Published 08 March 1997) Cite this as: BMJ 1997;314:695
  1. Alison Boulton
  1. London

    A United States National Institutes of Health trial of patients with advanced HIV disease has been stopped early because a combination of three drugs showed significant benefits.

    The US National Institute of Allergy and Infectious Diseases study known as ACTG 320 examined the safety and efficacy of adding a protease inhibitor (indinavir) to two nucleoside analogue reverse transcriptase inhibitors-zidovudine and lamivudine. …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription